UBS Group
BLFS icon

UBS Group’s BioLife Solutions BLFS Stock Holding History

UBS Group’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,500
Closed -$1.06M – 9390
2021
Q1 		$1.06M Hold
29,500
– – ﹤0.01% 4181
2020
Q4 		$1.18M Buy
+29,500
New +$1.01M ﹤0.01% 3881

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS Group's BLFS Position: Q2 2026 in Review

UBS Group increased its BioLife Solutions (BLFS) stake by 213% in Q2 2026, buying an estimated $13.2M and bringing the position to 832,143 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

UBS Group first reported a position in BLFS in Q4 2014 and has held it in 40 quarters since. 216 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

  • UBS Group held 832,143 shares of BioLife Solutions worth $23.5M as of Q2 2026.
  • UBS Group bought 566,165 BioLife Solutions shares in Q2 2026, an estimated $13.2M.
  • BioLife Solutions made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2514 holding.
  • UBS Group first reported a position in BioLife Solutions in Q4 2014 and has held it in 40 quarters since.
  • 216 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.